Recombinant antibodies specific for TNF.alpha.

US5994510A · kind A · utility

Assignee

• Celltech Therapeutics Limited · GB

Inventors

• John Robert Adair · Paragon Road, GB
• Diljeet Singh Athwal · London, GB
• John Spencer Emtage · Del Mar, US
• Mark Bodmer · South Hinksey, GB

Key dates

• Filing date: Jun 1, 1995
• Grant date: Nov 30, 1999
• Expiry date: Jun 1, 2015

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Recombinant, in particular humanised, e.g. humanised chimeric and CDR-grafted humanised, antibody molecules having specificity for human TNF.alpha., are provided for use in diagnosis and therapy. In particular, the antibody molecules have antigen binding sites derived from murine monoclonal antibodies CB0006, CB0010, hTNF3 or 101.4. Preferred CDR-grafted humanised anti-hTNF.alpha. antibodies comprise variable region domains comprising human acceptor framework and donor antigen binding regions and wherein the frameworks comprise donor residues at specific positions. The antibody molecules may be used for therapeutic treatment of human patients suffering from or at risk of disorders associated with undesirably high levels of TNF, in particular for treatment of immunoregulatory and inflammatory disorders or of septic, endotoxic or cardiovascular shock.